Profile: Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

105.00DKK
10:59am EDT
Price Change (% chg)

kr.-1.50 (-1.41%)
Prev Close
kr.106.50
Open
kr.107.00
Day's High
kr.109.00
Day's Low
kr.104.00
Volume
161,638
Avg. Vol
111,386
52-wk High
kr.110.00
52-wk Low
kr.54.50

Search Stocks
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines within biodefence, cancer and infectious diseases therapeutic areas. The Company operates within two segments: Cancer Vaccines and Infectious Disease. The Cancer Vaccines’ pipeline is focused on therapeutic vaccines and includes two projects in prostate cancer, PROSTVAC and MVA-BN PRO; two projects in breast cancer, CV-301 and MVA-BN HER2; one project in lung cancer, CV-301 lung, and one project in ovarian cancer, CV-301 ovarian. The Infectious Disease’s pipeline is focused on prophylactic vaccines and includes a smallpox vaccine candidate; an anthrax vaccine candidate, MVA-BN Anthrax, and a RSV vaccine candidate, MVA-BN RSV. Bavarian Nordic A/S has research centers in Mountain View in the United States and Martinsried in Germany, and manufacturing facilities in Kvistgaard, Denmark, and Berlin, Germany.

Company Address

Bavarian Nordic A/S

Hejreskovvej 10A
KVISTGAARD     3490

Search Stocks